As of 2024-12-14, the Intrinsic Value of Sarepta Therapeutics Inc (SRPT) is
6.38 USD. This SRPT valuation is based on the model Peter Lynch Fair Value.
With the current market price of 123.71 USD, the upside of Sarepta Therapeutics Inc is
-94.84%.
SRPT Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(663.59) - (187.94) |
(284.62) |
-330.1% |
| DCF (Growth 10y) |
(244.98) - (838.91) |
(366.50) |
-396.3% |
| DCF (EBITDA 5y) |
(135.29) - (166.09) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(190.33) - (248.09) |
(1,234.50) |
-123450.0% |
| Fair Value |
6.38 - 6.38 |
6.38 |
-94.84% |
| P/E |
24.06 - 54.90 |
34.31 |
-72.3% |
| EV/EBITDA |
14.05 - 29.94 |
17.95 |
-85.5% |
| EPV |
(60.58) - (81.04) |
(70.81) |
-157.2% |
| DDM - Stable |
13.14 - 61.14 |
37.14 |
-70.0% |
| DDM - Multi |
(104.80) - (383.30) |
(165.09) |
-233.4% |
SRPT Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
11,816.78 |
| Beta |
1.45 |
| Outstanding shares (mil) |
95.52 |
| Enterprise Value (mil) |
12,846.48 |
| Market risk premium |
4.60% |
| Cost of Equity |
8.34% |
| Cost of Debt |
4.39% |
| WACC |
7.97% |